23rd International AIDS Conference (AIDS 2020): second reports
6 – 10 July 2020, virtual meeting (was San Francisco and Santa Barbara).
The conference website is now available as an open access resource that no longer needs registration details.
Abstracts are now online, although the portal is still not always easy to navigate.
Many presentations are also online, but many also have withheld permission for these to be posted online. Perhaps these should not have been accepted for a virtual conference.
The following reports are included in this issue of HTB.
- Dolutegravir non-inferior to efavirenz at week 96 in the NAMSAL study but associated with substantial weight gain
- Switching from efavirenz- to dolutegravir-based ART second-line achieved good rates of suppression: first results from the VISEND study